206 related articles for article (PubMed ID: 18600558)
1. Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.
Okamoto K; Eger BT; Nishino T; Pai EF; Nishino T
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):888-93. PubMed ID: 18600558
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of urate bound form of xanthine oxidoreductase: substrate orientation and structure of the key reaction intermediate.
Okamoto K; Kawaguchi Y; Eger BT; Pai EF; Nishino T
J Am Chem Soc; 2010 Dec; 132(48):17080-3. PubMed ID: 21077683
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of the active and alloxanthine-inhibited forms of xanthine dehydrogenase from Rhodobacter capsulatus.
Truglio JJ; Theis K; Leimkühler S; Rappa R; Rajagopalan KV; Kisker C
Structure; 2002 Jan; 10(1):115-25. PubMed ID: 11796116
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the Inhibition Mechanism of Xanthine Oxidoreductase by Oxipurinol: A Computational Study.
Maghsoud Y; Dong C; Cisneros GA
J Chem Inf Model; 2023 Jul; 63(13):4190-4206. PubMed ID: 37319436
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitors of xanthine oxidoreductase].
Okamoto K
Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
7. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.
Fukunari A; Okamoto K; Nishino T; Eger BT; Pai EF; Kamezawa M; Yamada I; Kato N
J Pharmacol Exp Ther; 2004 Nov; 311(2):519-28. PubMed ID: 15190124
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.
Nakamura M; Fujita K; Toyoda Y; Takada T; Hasegawa H; Ichida K
Drug Metab Pharmacokinet; 2018 Feb; 33(1):77-81. PubMed ID: 29342419
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Okamoto K; Nishino T
J Nippon Med Sch; 2008 Feb; 75(1):2-3. PubMed ID: 18360072
[TBL] [Abstract][Full Text] [Related]
10. Oxipurinol: alloxanthine, Oxyprim, oxypurinol.
Drugs R D; 2004; 5(3):171-5. PubMed ID: 15139781
[TBL] [Abstract][Full Text] [Related]
11. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.
Okamoto K; Eger BT; Nishino T; Kondo S; Pai EF; Nishino T
J Biol Chem; 2003 Jan; 278(3):1848-55. PubMed ID: 12421831
[TBL] [Abstract][Full Text] [Related]
12. [Xanthine dehydrogenase (xanthine oxidase)].
Ichida K; Yamaguchi Y; Matsumura T
Nihon Rinsho; 2003 Jan; 61 Suppl 1():98-102. PubMed ID: 12629699
[No Abstract] [Full Text] [Related]
13. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.
Matsumoto K; Okamoto K; Ashizawa N; Nishino T
J Pharmacol Exp Ther; 2011 Jan; 336(1):95-103. PubMed ID: 20952484
[TBL] [Abstract][Full Text] [Related]
14. Effects of cassia oil on serum and hepatic uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver.
Zhao X; Zhu JX; Mo SF; Pan Y; Kong LD
J Ethnopharmacol; 2006 Feb; 103(3):357-65. PubMed ID: 16182482
[TBL] [Abstract][Full Text] [Related]
15. Chemical nature and reaction mechanisms of the molybdenum cofactor of xanthine oxidoreductase.
Okamoto K; Kusano T; Nishino T
Curr Pharm Des; 2013; 19(14):2606-14. PubMed ID: 23116398
[TBL] [Abstract][Full Text] [Related]
16. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
17. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
18. Effects of allopurinol on uric acid concentrations, xanthine oxidoreductase activity and oxidative stress in broiler chickens.
Carro MD; Falkenstein E; Radke WJ; Klandorf H
Comp Biochem Physiol C Toxicol Pharmacol; 2010 Jan; 151(1):12-7. PubMed ID: 19654053
[TBL] [Abstract][Full Text] [Related]
19. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical and kinetic properties of purified sheep's milk xanthine oxidoreductase.
Benboubetra M; Baghiani A; Atmani D; Harrison R
J Dairy Sci; 2004 Jun; 87(6):1580-4. PubMed ID: 15453470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
